Long-term results of a randomised trial comparing iridium implant plus external beam radiotherapy with external beam radiotherapy: beyond the abstract

Over the past decade, a number of randomised trials have shown improved biochemical control resulting from escalated doses of radiotherapy for men with prostate cancer.  Some of these trials have employed a brachytherapy boost, resulting in reductions of biochemical relapse in the order of 31-58%. Despite these clinically significant improvements in biochemical control, none of these studies have, to date, reported any benefit with respect to subsequent development of metastatic disease, prostate cancer-specific mortality or overall survival.